Khalifah Anthony P, Hachem Ramsey R, Chakinala Murali M, Yusen Roger D, Aloush Aviva, Patterson G Alexander, Mohanakumar Thalachallour, Trulock Elbert P, Walter Michael J
Department of Internal Medicine, University of Texas Southwestern Medical Center, Divisions of Pulmonary and Critical Care Medicine and Cardiothoracic Surgery at Washington University School of Medicine, St. Louis, Missouri, USA.
Am J Transplant. 2005 Aug;5(8):2022-30. doi: 10.1111/j.1600-6143.2005.00953.x.
Bronchiolitis obliterans syndrome (BOS) is a major cause of lung allograft dysfunction. Although previous studies have identified mild to severe rejection (grade>or=A2) as a risk factor for BOS, the role of minimal rejection (grade A1) remains unclear. To determine if A1 rejection by itself is a risk factor for BOS, we performed a retrospective cohort study on 228 adult lung transplant recipients over a 7-year period. Cohorts were defined by their most severe rejection episode (none, A1 only, and >or=A2) and analyzed for the subsequent development and progression of BOS using univariate and multivariate time-dependent Cox regression analysis. In the univariate model, the occurrence of isolated minimal rejection was a risk factor for all stages of BOS. Similarly, multivariate models that included HLA mismatch, cytomegalovirus pneumonitis, community acquired viral infection, underlying disease and type of transplant demonstrated that A1 rejection was a distinct risk factor for BOS. Furthermore, the associated risk with A1 rejection was slightly greater than the risk from >or=A2 and treatment of A1 rejection decreased the risk for subsequent BOS stage 1. We conclude that minimal rejection is associated with an increased risk for BOS development and progression that is comparable to A2 rejection.
闭塞性细支气管炎综合征(BOS)是肺移植功能障碍的主要原因。尽管先前的研究已将轻度至重度排斥反应(分级≥A2)确定为BOS的一个危险因素,但最小排斥反应(A1级)的作用仍不明确。为了确定A1排斥反应本身是否为BOS的危险因素,我们对228名成年肺移植受者进行了一项为期7年的回顾性队列研究。根据其最严重的排斥反应发作情况(无、仅A1级以及≥A2级)对队列进行定义,并使用单变量和多变量时间依赖性Cox回归分析对BOS的后续发展和进展进行分析。在单变量模型中,孤立性最小排斥反应的发生是BOS各个阶段的危险因素。同样,纳入HLA错配、巨细胞病毒性肺炎、社区获得性病毒感染、基础疾病和移植类型的多变量模型表明,A1排斥反应是BOS的一个明显危险因素。此外,A1排斥反应的相关风险略高于≥A2级排斥反应的风险,并且对A1排斥反应的治疗降低了后续BOS 1期的风险。我们得出结论,最小排斥反应与BOS发生和进展风险增加相关,这与A2排斥反应相当。